Key result
Diabetic foot complications linked to ~31% higher prevalence of cardiac autonomic neuropathy.
Why the study?
Cardiac autonomic neuropathy in people with diabetes is associated with high mortality, prompting evaluation of the age- and disease duration-independent prevalence of CAN in patients with diabetic foot complications.
Is the prevalence of cardiac autonomic neuropathy higher in diabetic patients with foot complications compared to those without?
Cross-Sectional (n=530)
Is the prevalence of cardiac autonomic neuropathy higher in diabetic patients with foot complications compared to those without?
Absolute Event Rate: 75.6% vs 57.9%
p-value: p=<0.001
Cardiac autonomic neuropathy is highly prevalent in diabetic patients with foot complications, particularly Charcot neuroarthropathy, highlighting the need for cardiovascular risk assessment in this population.
Higher CAN prevalence in diabetic foot complications warrants targeted screening; observational data leaves open whether detection alters outcomes.
Introduction: Cardiac autonomic neuropathy (CAN) in people with diabetes is associated with high mortality. We aimed to study age and disease duration, independent prevalence of CAN in people with diabetic foot complications. Methods: 530 patients with diabetes were screened to undergo CAN assessment (automated CANS-analyser). CAN was defined as "early", "definite," or "severe" according to the Toronto consensus. History pertaining to autonomic symptoms, prior cardiovascular events (CVE), and assessment for peripheral neuropathy was done. Participants were grouped into those with diabetic foot complication (group A, n = 82) [Charcot foot (n = 42), diabetic foot ulcer (n = 40)]; with DPN without foot complications (group B, n = 82); and without DPN or foot complications (group C, n = 82). Results: Symptoms of autonomic dysfunction were prominent in people with foot complications than the other groups. Resting heart rate was significantly greater in those with foot complications [99.89 ± 26.71 (group A) vs. 86.99 ± 22.24 (group B) vs. 88.32 ± 17.08 (group C); P = 0.001]. The prevalence of CAN was 75.6% in group A (51.2% early, 12.2% definite, 12.2% severe), 57.2% in group B (45.1% early, 12.2% severe) and 58.5% in group C (43.9% early, 1.2% definite, 13.4% severe) (P = 0.002). Patients with foot complications were more likely to have CAN (75.6% vs. 57.9%, P < 0.001). Charcot foot had higher prevalence of CAN (78.6%) as compared with those with DFU (72.5%) or without DFU or DPN (57.9%), P < 0.001. Conclusion: CAN is present in more than two-third of patients with diabetes and foot complications with highest prevalence in Charcot neuroarthropathy.
No takes yet. Share an insight, caveat, or question.
Wadhera et al. (2022) conducted a cross-sectional in Diabetes (n=530). Diabetic foot complications vs. Patients without diabetic foot complications was evaluated on Prevalence of cardiac autonomic neuropathy (CAN) (p=<0.001). Diabetic foot complications were associated with a significantly higher prevalence of cardiac autonomic neuropathy compared to patients without foot complications (75.6% vs. 57.9%, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: